Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Technology Stocks : SYNSORB (T.SYB)(SYBBF) CURE FOR CANCER? -- Ignore unavailable to you. Want to Upgrade?

To: Tupulak who wrote (91)	1/23/2000 4:23:00 PM
From: Sea Otter	Read Replies (1) \| Respond to of 164

See attached. Synsorb gets a mention, along with Biomira. Been following this one for awhile. Bought Friday. I like these cheap biotechs that 1) have good science and 2) are far along in trials. And I think I may start a new thread - that "Cure For Cancer" item doesn't quite fit. ====================== 1/20/00 Paul Able, Manager of ?The Medical Fund? Some of the small cap companies that Paul sees having strong growth potential is the Canadian firm Biomira (NASDAQ: BIOM). Growth in the sector could be "explosive? The Medical Fund evaluates companies using two criteria. First the company must have "compelling" science. The product or treatment they are working to develop must have a strong scientific basis. Secondly, the company must have strong finances or alliances to allow it to complete testing and obtain FDA approval of potential products. All have substantial potential products in the pipeline, and the ability to move the development down the pipeline with their financial strength or alliances. theaudioinvestor.com 1/21/00 Biomira shares surge 35% by Leonard Zehr - Friday, January 21, 2000 Groome Capital Inc.: Mr. Camir‚ said an unprecedented number of biotech companies are entering the last phase of clinical trials and will be launching new products, "creating an increasing number of reasons to get back into the sector." After biotech stocks hit rock bottom last year, "we believe the sector is due for a comeback and we have already seen early signs of this happening," said Claude Camir‚, an analyst with Groome Capital Inc Dlouhy Investments Inc.: said four companies -- Hemosol, Synsorb, Biomira and AnorMed Inc. of Langley, B.C. -- are currently in Phase III clinical trials,. "A large portion of the risk in biotech is removed after Phase II results," he said. "Yet these companies don't seem to get the recognition in the market until after Phase III." Edmonton-based Biomira currently is conducting a major Phase III clinical trial for its Theratope breast cancer vaccine and a Phase II trial for a lung cancer vaccine, BLP-25.